Navigation Links
Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Date:5/31/2009

KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer

NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Abstract #4081, entitled, "Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer," is being presented today in a poster during the Gastrointestinal Cancer - Colorectal session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida.

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, patients with 2nd or 3rd line metastatic colon cancer were randomized to receive capecitabine (Xeloda(R)), an approved drug for metastatic colon cancer, at a dose of 825 mg/m2 BID (total daily dose of 1650 mg/m2) on days 1 - 14 every 21 days, plus either perifosine or placebo at 50 mg daily. Treatment was continued until progression. The study enrolled a total of 38 patients, of which 35 patients were evaluable for response (20 patients on the capecitabine + perifosine arm and 15 patients on the capecitabine + placebo arm). The three patients not evaluable for response were all in the capecitabine + placebo arm; 2 patients were inevaluable due to toxicity (days 14, 46) and 1 patient was inevaluable due to a new malignancy on day 6.

The median prior treatment regimens was two, with prior treatment regimens as follows: 91% of the patients r
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 ... effets du décalage horaire. Il nuit sérieusement ... de concentration durant les réunions de mi-journée ... réveillant au mauvais moment dans votre chambre ... le décalage horaire risque de vous empêcher ...
(Date:5/27/2015)... May 27, 2015 Water Street ... on the health care industry, announced today that ... one of the world,s leading global health care ... which the firm established in 2013 as a ... investment in developing pharmaceutical products and medical devices. ...
(Date:5/27/2015)... DUBLIN , May 25, 2015 ... addition of the "2015 Strategies in the ... offering. This comprehensive seven-country report contains ... help current suppliers and potential market entrants identify ... coagulation testing market during the next five years. ...
Breaking Medicine Technology:HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 2HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 3HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 4Water Street Announces Pharmaceutical Development Partnership with Global Health Care Company 2Global Coagulation Testing Market Strategies 2015 2Global Coagulation Testing Market Strategies 2015 3
... Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ... announced today the submission of its Device Master File ... for its patented OncoSec Medical System (OMS) ... Company has been developing the OncoSec Medical System as ...
... Oct. 20, 2011 Comprehensive Care Corporation (OTC BB: ... pharmacy management services for managed care companies throughout the ... CEO, has been praised by the Chamber of Commerce ... Corporate Leadership Advisory Council in "helping to shape and ...
Cached Medicine Technology:Device Master File for OncoSec Medical System Completed and Submitted to FDA 2Device Master File for OncoSec Medical System Completed and Submitted to FDA 3Comprehensive Care Corporation CEO Clark A. Marcus Praised for U.S. Chamber of Commerce Service 2
(Date:5/27/2015)... 27, 2015 The BBB Code of ... practices that enhance customer trust and confidence in business. ... Trust, eight principles that summarize important elements of creating ... standards for business accreditation by BBB. Businesses based in ... and complete application procedures will be accredited by BBB. ...
(Date:5/27/2015)... May 27, 2015 With the launch ... more robust Network Management Module (NMM) tool, monitoring provider-network ... 21 issue of Atlantic Information Services, Inc.’s (AIS) Medicare ... NMM tool, as well as analysis from industry experts ... The changes coming to the NMM were announced at ...
(Date:5/27/2015)... Austin, TX (PRWEB) May 27, 2015 ... gas information. Topics include: Why investors should consider oil ... investors, how and why wells are drilled, industry news, ... , Carson Energy's 32 years of knowledge and experience ... and gas investment community to be able to access ...
(Date:5/27/2015)... May 27, 2015 The Case ... a partnership to provide CMSA's Career and Knowledge ... collaboration seeks to strengthen the case/care management workforce ... CKP program. The mutually beneficial agreement provides Medix, ... skills of talent in the healthcare, scientific and ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Coco Libre announced ... be able to reach for Organic Coconut Water to quench ... will be available at VIP areas, artist greenrooms, corporate skyboxes ... available at area hotels and on festival shuttle buses. ... this year,” said Noa Elan, Director of Strategic Partnerships for ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2
... New Zealand Aids Foundation has welcomed a decision by Pharmac(the ... the same time, they say delays over the funding may ... medicines, to be subsidized from April 1, 2007 are Tenofovir ... to Pharmac’s medical director Dr Peter Moodie the investment would ...
... slower in children who wear a special kind of ... lenses// according to a new study published in Investigative ... found that among children with two myopic parents, myopia ... when compared to those wearing single-vision lenses (SVLs).Knowing parental ...
... by a specialist headache centre, it was observed that eight ... at work; 91 per cent blamed the ineffectiveness to headaches, ... published in the March issue of Cephalalgia. ,"Migraines ... when they are often at their most productive, so the ...
... suggests that genes responsible for generating matrix metalloproteinase 1 ... long term hip replacement surgery. ,The researchers ... of whom (162) had problems after hip replacement in ... with symptoms, 91 had early signs of 'aseptic loosening,' ...
... SAN DIEGO--(BUSINESS WIRE)--Ichor Medical Systems, whose advanced electroporation ... effectiveness// of DNA drug and vaccine delivery, has ... $900,000 by the United States Department of Defense ... Institute of Infectious Diseases (USAMRIID) in Fort Detrick, ...
... certainly be an indicator of one’s happiness. Researchers at the ... nation's overall happiness and its citizens' blood pressure problems. ... across the European countries. ,These people were asked how happy ... blood pressure) and so on. ,While Sweden, Denmark ...
Cached Medicine News:Health News:New Zealand’s Pharmac Subsidies Two More HIV Drug 2Health News:Work Absence Due to Headaches Has a Substantial Socio-economic Effect 2Health News:United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine 2
Tested by surgeons for functionality and ergonomy. Uses the Medifix C3-3001-3CCD camera head....
Integrated electronics, three-chip CCD camera with PAL and NTSC output at 750 lines, RGB-video. 44mm x 49mm x 75mm, 180 grams....
Large image and wide-angle design....
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
Medicine Products: